Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15686984,run time,The chromatographic run time was within 15 min.,Ion-pair reverse-phase high performance liquid chromatography method for determination of Huperzine-A in beagle dog serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686984/),min,15,888,DB00643,Mebendazole
,28981899,LC50,The carbazole aminoalcohols exhibited potent protoscolicidal activity with LC50 values ranging from 18.2 to 34.3 μM.,In vitro and in vivo efficacies of novel carbazole aminoalcohols in the treatment of cystic echinococcosis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28981899/),μM,18.2 to 34.3,2142,DB00643,Mebendazole
>,28981899,oral bioavailability,Pharmacokinetic profiling of compounds 2 and 24 revealed low clearance and decent oral bioavailability (>70%).,In vitro and in vivo efficacies of novel carbazole aminoalcohols in the treatment of cystic echinococcosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28981899/),%,70,2143,DB00643,Mebendazole
,21797012,LODs,The LODs ranged from 0.08 to 2.0 microg/kg and the LOQs from 0.3 to 5.0 microg/kg.,Simultaneous determination of benzimidazoles and their metabolites in plasma using high-performance liquid chromatography/tandem mass spectrometry: application to pharmacokinetic studies in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797012/),[μg] / [kg],0.08 to 2.0,12834,DB00643,Mebendazole
,21797012,LOQs,The LODs ranged from 0.08 to 2.0 microg/kg and the LOQs from 0.3 to 5.0 microg/kg.,Simultaneous determination of benzimidazoles and their metabolites in plasma using high-performance liquid chromatography/tandem mass spectrometry: application to pharmacokinetic studies in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797012/),[μg] / [kg],0.3 to 5.0,12835,DB00643,Mebendazole
,24874646,AUC 0-LOQ,"In rats, FLBZ systemic exposure (AUC 0-LOQ) was significantly (P < 0.05) higher after the FLBZ-CD treatments, both oral (4.8 ± 0.9 µg.h/mL) and subcutaneous (7.3 ± 0.6 µg.h/mL), compared to that observed after oral administration of FLBZ-CMC suspension (0.93 ± 0.2 µg.h/mL).",Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874646/),[h·μg] / [ml],4.8,17575,DB00643,Mebendazole
,24874646,AUC 0-LOQ,"In rats, FLBZ systemic exposure (AUC 0-LOQ) was significantly (P < 0.05) higher after the FLBZ-CD treatments, both oral (4.8 ± 0.9 µg.h/mL) and subcutaneous (7.3 ± 0.6 µg.h/mL), compared to that observed after oral administration of FLBZ-CMC suspension (0.93 ± 0.2 µg.h/mL).",Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874646/),[h·μg] / [ml],7.3,17576,DB00643,Mebendazole
,24874646,AUC 0-LOQ,"In rats, FLBZ systemic exposure (AUC 0-LOQ) was significantly (P < 0.05) higher after the FLBZ-CD treatments, both oral (4.8 ± 0.9 µg.h/mL) and subcutaneous (7.3 ± 0.6 µg.h/mL), compared to that observed after oral administration of FLBZ-CMC suspension (0.93 ± 0.2 µg.h/mL).",Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874646/),[h·μg] / [ml],0.93,17577,DB00643,Mebendazole
,30650076,oral bioavailability,"In animals, flubendazole has good oral bioavailability from an ASD formulation ranging from 15% in dogs, 27% in rats to more than 100% in jirds.",Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650076/),%,15,24523,DB00643,Mebendazole
,30650076,oral bioavailability,"In animals, flubendazole has good oral bioavailability from an ASD formulation ranging from 15% in dogs, 27% in rats to more than 100% in jirds.",Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650076/),%,27,24524,DB00643,Mebendazole
more,30650076,oral bioavailability,"In animals, flubendazole has good oral bioavailability from an ASD formulation ranging from 15% in dogs, 27% in rats to more than 100% in jirds.",Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650076/),%,100,24525,DB00643,Mebendazole
lower,30650076,NOAEL,"In dogs, the NOAEL was lower than 20 mg eq./kg/day.",Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650076/),[eq·mg] / [d·kg],20,24526,DB00643,Mebendazole
,29648826,oral bioavailability,"When evaluated in mice, 12 displayed a 2.2-fold higher plasma AUC0- t and a 1.7-fold improvement in brain AUC0- t with a calculated oral bioavailability of 52%, as compared to 24% for MBZ-polymorph C (MBZ-C), the most bioavailable polymorph.",N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648826/),%,52,50107,DB00643,Mebendazole
,29648826,oral bioavailability,"When evaluated in mice, 12 displayed a 2.2-fold higher plasma AUC0- t and a 1.7-fold improvement in brain AUC0- t with a calculated oral bioavailability of 52%, as compared to 24% for MBZ-polymorph C (MBZ-C), the most bioavailable polymorph.",N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648826/),%,24,50108,DB00643,Mebendazole
,29648826,oral bioavailability,"In dogs, 12 showed a 3.8-fold higher plasma AUC0- t with oral bioavailability of 41% compared to 11% for MBZ-C.",N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648826/),%,41,50109,DB00643,Mebendazole
,29648826,oral bioavailability,"In dogs, 12 showed a 3.8-fold higher plasma AUC0- t with oral bioavailability of 41% compared to 11% for MBZ-C.",N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648826/),%,11,50110,DB00643,Mebendazole
,10761730,absorption half-life (K01-HL),"Oral absorption is rapid compared with IM dosing; the absorption half-life (K01-HL) for the IM treatment is approximately 14 hr compared with 1 and 2 hr for the PO regimen of salt and free base forms, respectively.","Pharmacokinetics of UMF-078, a candidate antifilarial drug, in infected dogs. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761730/),h,14,54268,DB00643,Mebendazole
,10761730,absorption half-life (K01-HL),"Oral absorption is rapid compared with IM dosing; the absorption half-life (K01-HL) for the IM treatment is approximately 14 hr compared with 1 and 2 hr for the PO regimen of salt and free base forms, respectively.","Pharmacokinetics of UMF-078, a candidate antifilarial drug, in infected dogs. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761730/),h,1,54269,DB00643,Mebendazole
,10761730,absorption half-life (K01-HL),"Oral absorption is rapid compared with IM dosing; the absorption half-life (K01-HL) for the IM treatment is approximately 14 hr compared with 1 and 2 hr for the PO regimen of salt and free base forms, respectively.","Pharmacokinetics of UMF-078, a candidate antifilarial drug, in infected dogs. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761730/),h,2,54270,DB00643,Mebendazole
,10761730,elimination half-lives (K10-HL),"The elimination half-lives (K10-HL) for the PO regimens are 13 and 15 hr for the salt and free base forms, respectively.","Pharmacokinetics of UMF-078, a candidate antifilarial drug, in infected dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761730/),h,13,54271,DB00643,Mebendazole
,10761730,elimination half-lives (K10-HL),"The elimination half-lives (K10-HL) for the PO regimens are 13 and 15 hr for the salt and free base forms, respectively.","Pharmacokinetics of UMF-078, a candidate antifilarial drug, in infected dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761730/),h,15,54272,DB00643,Mebendazole
,27120064,Cmax,"The oral administration of the HPBCD-solution accounted for significantly higher (P < 0.05) Cmax and AUC (23.1 ± 4.4 μg h/mL) values for the main metabolite (H-FLBZ), compared with those observed for the oral CMC-suspension (AUC = 3.5 ± 1.0 μg h/mL) and injectable Tween 80-based formulation (AUC: 7.5 ± 1.7 μg h/mL).",Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120064/),[h·μg] / [ml],23.1,67133,DB00643,Mebendazole
,27120064,AUC,"The oral administration of the HPBCD-solution accounted for significantly higher (P < 0.05) Cmax and AUC (23.1 ± 4.4 μg h/mL) values for the main metabolite (H-FLBZ), compared with those observed for the oral CMC-suspension (AUC = 3.5 ± 1.0 μg h/mL) and injectable Tween 80-based formulation (AUC: 7.5 ± 1.7 μg h/mL).",Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120064/),[h·μg] / [ml],3.5,67134,DB00643,Mebendazole
,27120064,AUC,"The oral administration of the HPBCD-solution accounted for significantly higher (P < 0.05) Cmax and AUC (23.1 ± 4.4 μg h/mL) values for the main metabolite (H-FLBZ), compared with those observed for the oral CMC-suspension (AUC = 3.5 ± 1.0 μg h/mL) and injectable Tween 80-based formulation (AUC: 7.5 ± 1.7 μg h/mL).",Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120064/),[h·μg] / [ml],7.5,67135,DB00643,Mebendazole
,7914496,pH peak activity,This reductase activity was characterized by NADPH dependency and a pH peak activity of 6.0 and was competitively inhibited by daunomycin.,Fasciola hepatica: mebendazole and thiabendazole pharmacokinetics in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914496/),,6.0,72181,DB00643,Mebendazole
,3978023,distribution half-life,"Following intravenous administration, the average distribution half-life, elimination half-life and rate of clearance were 0.20 h, 1.12 h, and 1.063 min respectively.",The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978023/),h,0.20,72974,DB00643,Mebendazole
,3978023,elimination half-life,"Following intravenous administration, the average distribution half-life, elimination half-life and rate of clearance were 0.20 h, 1.12 h, and 1.063 min respectively.",The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978023/),h,1.12,72975,DB00643,Mebendazole
,3978023,rate of clearance,"Following intravenous administration, the average distribution half-life, elimination half-life and rate of clearance were 0.20 h, 1.12 h, and 1.063 min respectively.",The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978023/),min,1.063,72976,DB00643,Mebendazole
,3978023,elimination half-life,"After oral administration of the solution, the average elimination half-life was 0.93 h, the apparent rate of clearance was 0.846 l/min, the average time to peak plasma concentration was 0.42 h, and the bioavailability of mebendazole was 22%.",The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978023/),h,0.93,72977,DB00643,Mebendazole
,3978023,apparent rate of clearance,"After oral administration of the solution, the average elimination half-life was 0.93 h, the apparent rate of clearance was 0.846 l/min, the average time to peak plasma concentration was 0.42 h, and the bioavailability of mebendazole was 22%.",The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978023/),[l] / [min],0.846,72978,DB00643,Mebendazole
,3978023,time to peak plasma concentration,"After oral administration of the solution, the average elimination half-life was 0.93 h, the apparent rate of clearance was 0.846 l/min, the average time to peak plasma concentration was 0.42 h, and the bioavailability of mebendazole was 22%.",The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978023/),h,0.42,72979,DB00643,Mebendazole
,3978023,bioavailability,"After oral administration of the solution, the average elimination half-life was 0.93 h, the apparent rate of clearance was 0.846 l/min, the average time to peak plasma concentration was 0.42 h, and the bioavailability of mebendazole was 22%.",The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978023/),%,22,72980,DB00643,Mebendazole
,19004671,flow rate,"Chromatographic separations were performed on a Chiralcel OD-R 250 mm x 4.6mm column with mobile phase methanol-1M NaClO(4) (75:25, v/v) at the flow rate 0.5 ml min(-1).",Sensitive chiral high-performance liquid chromatographic determination of anthelmintic flubendazole and its phase I metabolites in blood plasma using UV photodiode-array and fluorescence detection Application to pharmacokinetic studies in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19004671/),[ml] / [min],0.5,84634,DB00643,Mebendazole
,21256094,flow rate,"Chromatographic separation was carried on an Agilent HC-C(8) column (150 mm × 4.6 mm, 5 μm) at 40°C, with a mobile phase consisting of acetonitrile-10 mM ammonium acetate (70:30, v/v), a flow rate of 0.5 mL/min and a total run time of 6 min.",A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256094/),[ml] / [min],0.5,87532,DB00643,Mebendazole
,21256094,total run time,"Chromatographic separation was carried on an Agilent HC-C(8) column (150 mm × 4.6 mm, 5 μm) at 40°C, with a mobile phase consisting of acetonitrile-10 mM ammonium acetate (70:30, v/v), a flow rate of 0.5 mL/min and a total run time of 6 min.",A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256094/),min,6,87533,DB00643,Mebendazole
,29346367,Cmax,"ABZSO Cmax in serum was 1.20 ± 0.44 μg/mL, reached at 4.75 h post-treatment.",Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29346367/),[μg] / [ml],1.20,88675,DB00643,Mebendazole
,29346367,Cmax,"In urine, ABZSO Cmax was 3.24 ± 1.51 μg/mL reached at 6.50 h post-ABZ administration.",Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29346367/),[μg] / [ml],3.24,88676,DB00643,Mebendazole
,23529958,relative bioavailability,"Compared with the ABZ suspension groups, the relative bioavailability values of ABZ and ABZSX were 146.05 and 222.15%, respectively.",Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529958/),%,146.05,96016,DB00643,Mebendazole
,23529958,relative bioavailability,"Compared with the ABZ suspension groups, the relative bioavailability values of ABZ and ABZSX were 146.05 and 222.15%, respectively.",Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529958/),%,222.15,96017,DB00643,Mebendazole
,11262000,overall extraction recovery,"The overall extraction recovery values for flubendazole, the hydrolyzed metabolite, and the reduced metabolite in eggs (fortification levels of 200, 400, and 800 microg kg(-1)) and muscle (fortification levels of 25, 50, and 100 microg kg(-1)) were, respectively, 77, 78, and 80% and 92, 95, and 90%.",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),%,77,112385,DB00643,Mebendazole
,11262000,overall extraction recovery,"The overall extraction recovery values for flubendazole, the hydrolyzed metabolite, and the reduced metabolite in eggs (fortification levels of 200, 400, and 800 microg kg(-1)) and muscle (fortification levels of 25, 50, and 100 microg kg(-1)) were, respectively, 77, 78, and 80% and 92, 95, and 90%.",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),%,78,112386,DB00643,Mebendazole
,11262000,overall extraction recovery,"The overall extraction recovery values for flubendazole, the hydrolyzed metabolite, and the reduced metabolite in eggs (fortification levels of 200, 400, and 800 microg kg(-1)) and muscle (fortification levels of 25, 50, and 100 microg kg(-1)) were, respectively, 77, 78, and 80% and 92, 95, and 90%.",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),%,80,112387,DB00643,Mebendazole
,11262000,overall extraction recovery,"The overall extraction recovery values for flubendazole, the hydrolyzed metabolite, and the reduced metabolite in eggs (fortification levels of 200, 400, and 800 microg kg(-1)) and muscle (fortification levels of 25, 50, and 100 microg kg(-1)) were, respectively, 77, 78, and 80% and 92, 95, and 90%.",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),%,92,112388,DB00643,Mebendazole
,11262000,overall extraction recovery,"The overall extraction recovery values for flubendazole, the hydrolyzed metabolite, and the reduced metabolite in eggs (fortification levels of 200, 400, and 800 microg kg(-1)) and muscle (fortification levels of 25, 50, and 100 microg kg(-1)) were, respectively, 77, 78, and 80% and 92, 95, and 90%.",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),%,95,112389,DB00643,Mebendazole
,11262000,overall extraction recovery,"The overall extraction recovery values for flubendazole, the hydrolyzed metabolite, and the reduced metabolite in eggs (fortification levels of 200, 400, and 800 microg kg(-1)) and muscle (fortification levels of 25, 50, and 100 microg kg(-1)) were, respectively, 77, 78, and 80% and 92, 95, and 90%.",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),%,90,112390,DB00643,Mebendazole
,11262000,limits of detection,"The limits of detection for flubendazole and its hydrolyzed and reduced metabolites in egg and muscle were, respectively, 0.19, 0.29, and 1.14 microg kg(-1) and 0.14, 0.75, and 0.31 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],0.19,112391,DB00643,Mebendazole
,11262000,limits of detection,"The limits of detection for flubendazole and its hydrolyzed and reduced metabolites in egg and muscle were, respectively, 0.19, 0.29, and 1.14 microg kg(-1) and 0.14, 0.75, and 0.31 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],0.29,112392,DB00643,Mebendazole
,11262000,limits of detection,"The limits of detection for flubendazole and its hydrolyzed and reduced metabolites in egg and muscle were, respectively, 0.19, 0.29, and 1.14 microg kg(-1) and 0.14, 0.75, and 0.31 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],1.14,112393,DB00643,Mebendazole
,11262000,limits of detection,"The limits of detection for flubendazole and its hydrolyzed and reduced metabolites in egg and muscle were, respectively, 0.19, 0.29, and 1.14 microg kg(-1) and 0.14, 0.75, and 0.31 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],0.14,112394,DB00643,Mebendazole
,11262000,limits of detection,"The limits of detection for flubendazole and its hydrolyzed and reduced metabolites in egg and muscle were, respectively, 0.19, 0.29, and 1.14 microg kg(-1) and 0.14, 0.75, and 0.31 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],0.75,112395,DB00643,Mebendazole
,11262000,limits of detection,"The limits of detection for flubendazole and its hydrolyzed and reduced metabolites in egg and muscle were, respectively, 0.19, 0.29, and 1.14 microg kg(-1) and 0.14, 0.75, and 0.31 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],0.31,112396,DB00643,Mebendazole
,11262000,maximum residue limit,"For the trial with the recommended dose of 19.9 mg kg(-1), one day after the end of the treatment, the mean sum of the flubendazole plus hydrolyzed metabolite residue values in thigh and breast muscle declined to below the maximum residue limit (50 microg kg(-1)) and were, respectively, 36.6 and 54.1 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],50,112397,DB00643,Mebendazole
,11262000,maximum residue limit,"For the trial with the recommended dose of 19.9 mg kg(-1), one day after the end of the treatment, the mean sum of the flubendazole plus hydrolyzed metabolite residue values in thigh and breast muscle declined to below the maximum residue limit (50 microg kg(-1)) and were, respectively, 36.6 and 54.1 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],36.6,112398,DB00643,Mebendazole
,11262000,maximum residue limit,"For the trial with the recommended dose of 19.9 mg kg(-1), one day after the end of the treatment, the mean sum of the flubendazole plus hydrolyzed metabolite residue values in thigh and breast muscle declined to below the maximum residue limit (50 microg kg(-1)) and were, respectively, 36.6 and 54.1 microg kg(-1).",Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262000/),[μg] / [kg],54.1,112399,DB00643,Mebendazole
,15500567,plasma AUC ratios,"The plasma AUC ratios for R-FLBZ and FLBZ (AUC(R-FLBZ)/AUC(FLBZ)) were 4.07 i.v. and 5.55 i.r., respectively.","Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500567/),,4.07,115267,DB00643,Mebendazole
,15500567,plasma AUC ratios,"The plasma AUC ratios for R-FLBZ and FLBZ (AUC(R-FLBZ)/AUC(FLBZ)) were 4.07 i.v. and 5.55 i.r., respectively.","Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500567/),,5.55,115268,DB00643,Mebendazole
,15500567,AUC,"The plasma AUC ratios for R-FLBZ and FLBZ (AUC(R-FLBZ)/AUC(FLBZ)) were 4.07 i.v. and 5.55 i.r., respectively.","Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500567/),,4.07,115269,DB00643,Mebendazole
,15500567,AUC,"The plasma AUC ratios for R-FLBZ and FLBZ (AUC(R-FLBZ)/AUC(FLBZ)) were 4.07 i.v. and 5.55 i.r., respectively.","Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500567/),,5.55,115270,DB00643,Mebendazole
,15500567,C(max),R-FLBZ achieved a significantly higher (P < 0.01) C(max) value (0.14 microg/mL at 17.3 h post-treatment) than that observed for the parent drug FLBZ (0.04 microg/mL at 14.4 h post-treatment).,"Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500567/),[μg] / [ml],0.14,115271,DB00643,Mebendazole
,15500567,C(max),R-FLBZ achieved a significantly higher (P < 0.01) C(max) value (0.14 microg/mL at 17.3 h post-treatment) than that observed for the parent drug FLBZ (0.04 microg/mL at 14.4 h post-treatment).,"Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500567/),[μg] / [ml],0.04,115272,DB00643,Mebendazole
,15500567,rate,"Consistently, sheep liver microsomes metabolized FLBZ into its reduced metabolite at a rate of 9.46 +/- 2.72 nmol/mg/h.","Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500567/),[nM] / [h·mg],9.46,115273,DB00643,Mebendazole
,32062366,run time,The detection was performed on a quadrupole time-of-flight (Q-TOF) high-resolution mass spectrometer using positive electrospray ionization (ESI) source with a chromatographic run time of 6.0 min.,Pharmacokinetics and tissue distribution study of liposomal albendazole in naturally Echinococcus granulosus infected sheep by a validated UPLC-Q-TOF-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062366/),min,6.0,138851,DB00643,Mebendazole
,32062366,m,"The detection was operated using target ions of [M + H]+ at m/z 266.096 for ABZ, m/z 282.091 for ABZSO, m/z 298.086 for ABZSO2, m/z 240.081 for ABZSO2NH2 and m/z 296.104 for IS in selective ion mode, respectively.",Pharmacokinetics and tissue distribution study of liposomal albendazole in naturally Echinococcus granulosus infected sheep by a validated UPLC-Q-TOF-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062366/),,240.081,138852,DB00643,Mebendazole
,6617730,apparent total biliary clearance,One patient without cholestasis and with normal liver function had an apparent total biliary clearance (776 ml/min) which approached the hepatic plasma flow.,Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617730/),[ml] / [min],776,147970,DB00643,Mebendazole
,6617730,apparent total biliary clearance,The other patient with cholestasis and impairment of the hepatic drug metabolizing capacity showed a drastically reduced apparent total biliary clearance of 3.8 ml/min.,Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617730/),[ml] / [min],3.8,147971,DB00643,Mebendazole
,12408915,detection limit,"The assay was accurate and reproducible with a detection limit of 10 ng/ml for ABZ-SO, 2 ng/ml for ABZ-SO(2) and 4 ng/ml for ABZ-SO(2)-NH(2).",A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408915/),[ng] / [ml],10,148503,DB00643,Mebendazole
,12408915,detection limit,"The assay was accurate and reproducible with a detection limit of 10 ng/ml for ABZ-SO, 2 ng/ml for ABZ-SO(2) and 4 ng/ml for ABZ-SO(2)-NH(2).",A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408915/),[ng] / [ml],2,148504,DB00643,Mebendazole
,12408915,detection limit,"The assay was accurate and reproducible with a detection limit of 10 ng/ml for ABZ-SO, 2 ng/ml for ABZ-SO(2) and 4 ng/ml for ABZ-SO(2)-NH(2).",A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408915/),[ng] / [ml],4,148505,DB00643,Mebendazole
,8081473,recoveries,"The average recoveries of I, II and III over the concentration range 20-500 ng ml-1 were 69.9 +/- 4.7, 85.6 +/- 4.4 and 85.1 +/- 6.0%, respectively.",Determination of the antifilarial drug UMF-078 and its metabolites UMF-060 and flubendazole in whole blood using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8081473/),%,69.9,150765,DB00643,Mebendazole
,8081473,recoveries,"The average recoveries of I, II and III over the concentration range 20-500 ng ml-1 were 69.9 +/- 4.7, 85.6 +/- 4.4 and 85.1 +/- 6.0%, respectively.",Determination of the antifilarial drug UMF-078 and its metabolites UMF-060 and flubendazole in whole blood using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8081473/),%,85.6,150766,DB00643,Mebendazole
,8081473,recoveries,"The average recoveries of I, II and III over the concentration range 20-500 ng ml-1 were 69.9 +/- 4.7, 85.6 +/- 4.4 and 85.1 +/- 6.0%, respectively.",Determination of the antifilarial drug UMF-078 and its metabolites UMF-060 and flubendazole in whole blood using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8081473/),%,85.1,150767,DB00643,Mebendazole
,8081473,minimum detectable concentrations,"The minimum detectable concentrations in whole blood for I, II and III were 10, 7 and 7 ng ml-1, respectively.",Determination of the antifilarial drug UMF-078 and its metabolites UMF-060 and flubendazole in whole blood using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8081473/),[ng] / [ml],10,150768,DB00643,Mebendazole
,8081473,minimum detectable concentrations,"The minimum detectable concentrations in whole blood for I, II and III were 10, 7 and 7 ng ml-1, respectively.",Determination of the antifilarial drug UMF-078 and its metabolites UMF-060 and flubendazole in whole blood using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8081473/),[ng] / [ml],7,150769,DB00643,Mebendazole
,18207467,flow rate,"Inositol hexanicotinate and the internal standard (mebendazole) were separated isocratically using a mobile phase of acetonitrile/phosphate buffer (35:65, v/v, pH 6.0) at a flow rate of 1.0mL/min and a reverse-phase XTerra MS C(18) column (4.6mmx150mm, 3.5microm).",Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207467/),[ml] / [min],1.0,151164,DB00643,Mebendazole
,18207467,recovery,"At plasma concentrations of 1.5-100microg/mL, the mean recovery of inositol hexanicotinate was 99.6%.",Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207467/),%,99.6,151165,DB00643,Mebendazole
,22661241,area under the drug concentration-time curve (AUC(0-∞)),"The same was true that the area under the drug concentration-time curve (AUC(0-∞)) values of 19.8 (2.5)-28.2 (2.5) μg/ml × h revealed in the three MBZ-oil preparation groups was significantly higher than that of 11.6 (2.0) μg/ml × h in MBZ-1 % tragacanth group, and the bioavailability of the three MBZ-oil preparation groups was 71-143 % higher than that of MBZ-1 % tragacanth group.",Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22661241/),[μg] / [h·ml],19.8,151620,DB00643,Mebendazole
,22661241,area under the drug concentration-time curve (AUC(0-∞)),"The same was true that the area under the drug concentration-time curve (AUC(0-∞)) values of 19.8 (2.5)-28.2 (2.5) μg/ml × h revealed in the three MBZ-oil preparation groups was significantly higher than that of 11.6 (2.0) μg/ml × h in MBZ-1 % tragacanth group, and the bioavailability of the three MBZ-oil preparation groups was 71-143 % higher than that of MBZ-1 % tragacanth group.",Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22661241/),[μg] / [h·ml],28.2,151621,DB00643,Mebendazole
,22661241,area under the drug concentration-time curve (AUC(0-∞)),"The same was true that the area under the drug concentration-time curve (AUC(0-∞)) values of 19.8 (2.5)-28.2 (2.5) μg/ml × h revealed in the three MBZ-oil preparation groups was significantly higher than that of 11.6 (2.0) μg/ml × h in MBZ-1 % tragacanth group, and the bioavailability of the three MBZ-oil preparation groups was 71-143 % higher than that of MBZ-1 % tragacanth group.",Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22661241/),[μg] / [h·ml],11.6,151622,DB00643,Mebendazole
,22661241,bioavailability,"The same was true that the area under the drug concentration-time curve (AUC(0-∞)) values of 19.8 (2.5)-28.2 (2.5) μg/ml × h revealed in the three MBZ-oil preparation groups was significantly higher than that of 11.6 (2.0) μg/ml × h in MBZ-1 % tragacanth group, and the bioavailability of the three MBZ-oil preparation groups was 71-143 % higher than that of MBZ-1 % tragacanth group.",Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22661241/),%,71-143,151623,DB00643,Mebendazole
,7094986,elimination half-lives,"The mebendazole plasma concentration-time profiles differed considerably between patients; elimination half-lives ranged from 2.8-9.0 h, time to peak plasma concentration after dosing ranged from 1.5-7.25 h and peak plasma concentrations ranged from 17.5 to 500 ng/ml.",Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094986/),h,2.8-9.0,156437,DB00643,Mebendazole
,7094986,time to peak plasma concentration,"The mebendazole plasma concentration-time profiles differed considerably between patients; elimination half-lives ranged from 2.8-9.0 h, time to peak plasma concentration after dosing ranged from 1.5-7.25 h and peak plasma concentrations ranged from 17.5 to 500 ng/ml.",Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094986/),h,1.5-7.25,156438,DB00643,Mebendazole
,7094986,peak plasma concentrations,"The mebendazole plasma concentration-time profiles differed considerably between patients; elimination half-lives ranged from 2.8-9.0 h, time to peak plasma concentration after dosing ranged from 1.5-7.25 h and peak plasma concentrations ranged from 17.5 to 500 ng/ml.",Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094986/),[ng] / [ml],17.5 to 500,156439,DB00643,Mebendazole
,7094986,peak plasma concentration,The mean peak plasma concentration of mebendazole after an initial dose (69.5 ng/ml) was lower than found in patients during chronic therapy (137.4 ng/ml).,Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094986/),[ng] / [ml],69.5,156440,DB00643,Mebendazole
,7094986,peak plasma concentration,The mean peak plasma concentration of mebendazole after an initial dose (69.5 ng/ml) was lower than found in patients during chronic therapy (137.4 ng/ml).,Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094986/),[ng] / [ml],137.4,156441,DB00643,Mebendazole
,26827868,peak milk concentration,"However, the parent drug reached 0.01 μg/ml peak milk concentration at 10.66 h and AUCmilk/AUCplasma value was 0.18 ± 0.02 at a dosage of 20 mg/kg bodyweight.","Plasma disposition, milk excretion and parasitological efficacy of mebendazole in donkeys naturally infected by Cyathostominae. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26827868/),[μg] / [ml],0.01,188875,DB00643,Mebendazole
,26827868,AUCmilk/AUCplasma,"However, the parent drug reached 0.01 μg/ml peak milk concentration at 10.66 h and AUCmilk/AUCplasma value was 0.18 ± 0.02 at a dosage of 20 mg/kg bodyweight.","Plasma disposition, milk excretion and parasitological efficacy of mebendazole in donkeys naturally infected by Cyathostominae. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26827868/),,0.18,188876,DB00643,Mebendazole
,6673974,specific activity,The metabolism and pharmacokinetics of mebendazole was studied in rats using [2'-3H]-mebendazole (biologically stable; specific activity 383.9 (mCi/mMol) and [2-14C]-mebendazole (specific activity 2.57 mCi/mMol).,The metabolic and pharmacokinetic disposition of mebendazole in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673974/),[mci] / [mMol],383.9,195163,DB00643,Mebendazole
,6673974,specific activity,The metabolism and pharmacokinetics of mebendazole was studied in rats using [2'-3H]-mebendazole (biologically stable; specific activity 383.9 (mCi/mMol) and [2-14C]-mebendazole (specific activity 2.57 mCi/mMol).,The metabolic and pharmacokinetic disposition of mebendazole in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673974/),[mci] / [mMol],2.57,195164,DB00643,Mebendazole
,6673974,terminal plasma elimination half-life,Its terminal plasma elimination half-life was 3.2 hours and its re-distribution half-life was 0.4 hour.,The metabolic and pharmacokinetic disposition of mebendazole in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673974/),h,3.2,195165,DB00643,Mebendazole
,6673974,re-distribution half-life,Its terminal plasma elimination half-life was 3.2 hours and its re-distribution half-life was 0.4 hour.,The metabolic and pharmacokinetic disposition of mebendazole in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673974/),h,0.4,195166,DB00643,Mebendazole
,6673974,bioavailability,"After oral administration, as a solution in aqueous dimethyl sulphoxide, a bioavailability of 53% was obtained.",The metabolic and pharmacokinetic disposition of mebendazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6673974/),%,53,195167,DB00643,Mebendazole
,7126419,elimination half-life,"Following the intravenous administration of a tracer dose (1.7 microgram) of [3H]-mebendazole to a man, an elimination half-life of 1.16 h was observed and the volume of distribution was calculated to be 2.03 l/kg.",The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126419/),h,1.16,198856,DB00643,Mebendazole
,7126419,volume of distribution,"Following the intravenous administration of a tracer dose (1.7 microgram) of [3H]-mebendazole to a man, an elimination half-life of 1.16 h was observed and the volume of distribution was calculated to be 2.03 l/kg.",The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126419/),[l] / [kg],2.03,198857,DB00643,Mebendazole
,7126419,elimination half-life,"After oral administration of the same dose, an elimination half-life of 0.74 h was observed.",The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126419/),h,0.74,198858,DB00643,Mebendazole
,7126419,bioavailability,The bioavailability of mebendazole from the solution was found to be 17%.,The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7126419/),%,17,198859,DB00643,Mebendazole
,25862759,brain-to-plasma (B/P) ratio,"In addition, polymorph C demonstrated an AUC₀₋₂₄h brain-to-plasma (B/P) ratio of 0.82, whereas B showed higher plasma AUC and lower B/P ratio.",Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862759/),,0.82,216750,DB00643,Mebendazole
,21930885,area under the concentration-versus-time curve [AUC],FLBZ was detected in plasma (area under the concentration-versus-time curve [AUC] = 1.8 μg · h/ml) and cysts (AUC = 0.3 μg · h/g) collected from treated infected animals.,"Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [ml],1.8,225906,DB00643,Mebendazole
,21930885,AUC,FLBZ was detected in plasma (area under the concentration-versus-time curve [AUC] = 1.8 μg · h/ml) and cysts (AUC = 0.3 μg · h/g) collected from treated infected animals.,"Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [g],0.3,225907,DB00643,Mebendazole
,21930885,AUC,"Conversely, ABZSO was the only active molecule measured in plasma (AUC = 4.4 μg·h/ml) and cysts (AUC = 1.5 μg·h/g) after ABZ treatment.","Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [ml],4.4,225908,DB00643,Mebendazole
,21930885,AUC,"Conversely, ABZSO was the only active molecule measured in plasma (AUC = 4.4 μg·h/ml) and cysts (AUC = 1.5 μg·h/g) after ABZ treatment.","Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [g],1.5,225909,DB00643,Mebendazole
,26104502,recoveries,The mean recoveries of five targeted compounds from dog plasma ranged from 77 to 94%.,"Simultaneous determination of praziquantel, pyrantel embonate, febantel and its active metabolites, oxfendazole and fenbendazole, in dog plasma by liquid chromatography/mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26104502/),%,77 to 94,234601,DB00643,Mebendazole
,8335708,recoveries,"The average recoveries of I and MBZ over a concentration range of 25-250 ng/ml were 92.0 +/- 7.7 and 84.4 +/- 4.4%, respectively.","Determination of a new antifilarial drug, UMF-058, and mebendazole in whole blood by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8335708/),%,92.0,234928,DB00643,Mebendazole
,8335708,recoveries,"The average recoveries of I and MBZ over a concentration range of 25-250 ng/ml were 92.0 +/- 7.7 and 84.4 +/- 4.4%, respectively.","Determination of a new antifilarial drug, UMF-058, and mebendazole in whole blood by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8335708/),%,84.4,234929,DB00643,Mebendazole
,8335708,minimum detectable concentrations,"The minimum detectable concentrations in whole blood for I and MBZ were 7 and 6 ng/ml, respectively.","Determination of a new antifilarial drug, UMF-058, and mebendazole in whole blood by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8335708/),[ng] / [ml],7,234930,DB00643,Mebendazole
,8335708,minimum detectable concentrations,"The minimum detectable concentrations in whole blood for I and MBZ were 7 and 6 ng/ml, respectively.","Determination of a new antifilarial drug, UMF-058, and mebendazole in whole blood by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8335708/),[ng] / [ml],6,234931,DB00643,Mebendazole
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,7.7,245443,DB00643,Mebendazole
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,9.8,245444,DB00643,Mebendazole
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.8,245445,DB00643,Mebendazole
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.60,245446,DB00643,Mebendazole
,28401566,maximal drug plasma concentration,The maximal drug plasma concentration of 0.55 mg/L was achieved at 48 hr and then declined with the elimination half-life (T1/2β ) of 7.99 hr.,Plasma pharmacokinetics and muscle residue dynamics of mebendazole in Carassius auratus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28401566/),[mg] / [l],0.55,246711,DB00643,Mebendazole
,28401566,elimination half-life (T1/2β ),The maximal drug plasma concentration of 0.55 mg/L was achieved at 48 hr and then declined with the elimination half-life (T1/2β ) of 7.99 hr.,Plasma pharmacokinetics and muscle residue dynamics of mebendazole in Carassius auratus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28401566/),h,7.99,246712,DB00643,Mebendazole
,28401566,peak mebendazole concentration,Administration of 10 mg/kg by oral gavage for 5 successive days resulted in a peak mebendazole concentration of 0.70 mg/kg in muscle at 96 hr after the last dose.,Plasma pharmacokinetics and muscle residue dynamics of mebendazole in Carassius auratus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28401566/),[mg] / [kg],0.70,246713,DB00643,Mebendazole
,28401566,T1/2β,The drug was then eliminated at a relatively slow rate from muscle with T1/2β of 68.41 hr.,Plasma pharmacokinetics and muscle residue dynamics of mebendazole in Carassius auratus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28401566/),h,68.41,246714,DB00643,Mebendazole
,28401566,AUClast,"The AUClast in plasma and muscle was 19.42 and 105.33 mg hr/L, respectively.",Plasma pharmacokinetics and muscle residue dynamics of mebendazole in Carassius auratus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28401566/),[h·mg] / [l],19.42,246715,DB00643,Mebendazole
,28401566,AUClast,"The AUClast in plasma and muscle was 19.42 and 105.33 mg hr/L, respectively.",Plasma pharmacokinetics and muscle residue dynamics of mebendazole in Carassius auratus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28401566/),[h·mg] / [l],105.33,246716,DB00643,Mebendazole
,12586507,peak concentration (C(max),"On oral administration of colon-targeted tablets, mebendazole started appearing in the plasma at 5 h, and reached the peak concentration (C(max) of 25.7+/-2.6 ng/ml) at 9.4+/-1.7 h (T(max)) whereas the immediate release tablets produced peak plasma concentration (C(max) of 37.2+/-6.8 ng/ml) at 3.4+/-0.9 h (T(max)).",Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586507/),[ng] / [ml],25.7,249552,DB00643,Mebendazole
,12586507,T(max),"On oral administration of colon-targeted tablets, mebendazole started appearing in the plasma at 5 h, and reached the peak concentration (C(max) of 25.7+/-2.6 ng/ml) at 9.4+/-1.7 h (T(max)) whereas the immediate release tablets produced peak plasma concentration (C(max) of 37.2+/-6.8 ng/ml) at 3.4+/-0.9 h (T(max)).",Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586507/),h,9.4,249553,DB00643,Mebendazole
,12586507,peak plasma concentration (C(max),"On oral administration of colon-targeted tablets, mebendazole started appearing in the plasma at 5 h, and reached the peak concentration (C(max) of 25.7+/-2.6 ng/ml) at 9.4+/-1.7 h (T(max)) whereas the immediate release tablets produced peak plasma concentration (C(max) of 37.2+/-6.8 ng/ml) at 3.4+/-0.9 h (T(max)).",Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586507/),[ng] / [ml],37.2,249554,DB00643,Mebendazole
,12586507,T(max),"On oral administration of colon-targeted tablets, mebendazole started appearing in the plasma at 5 h, and reached the peak concentration (C(max) of 25.7+/-2.6 ng/ml) at 9.4+/-1.7 h (T(max)) whereas the immediate release tablets produced peak plasma concentration (C(max) of 37.2+/-6.8 ng/ml) at 3.4+/-0.9 h (T(max)).",Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586507/),h,3,249555,DB00643,Mebendazole
,32266168,Cmax,"The plasma concentration of S6 administered by both methods was very low, with the Cmax being only 1 ng/ml after oral administration and below the detection limit after intramuscular administration.",Pharmacophore-Based Virtual Screening Toward the Discovery of Novel Anti-echinococcal Compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32266168/),[ng] / [ml],1,262255,DB00643,Mebendazole
,27480864,50% inhibitory concentration [IC50],CYP1A2 showed a 2.6-fold increased inhibition by albendazole-oxantel pamoate (50% inhibitory concentration [IC50] = 3.1 μM) and a 3.9-fold increased inhibition by albendazole sulfoxide-mebendazole (IC50 = 3.8 μM) compared to the single drugs.,"In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480864/),μM,3.1,267180,DB00643,Mebendazole
,27480864,IC50,CYP1A2 showed a 2.6-fold increased inhibition by albendazole-oxantel pamoate (50% inhibitory concentration [IC50] = 3.1 μM) and a 3.9-fold increased inhibition by albendazole sulfoxide-mebendazole (IC50 = 3.8 μM) compared to the single drugs.,"In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480864/),μM,3.8,267181,DB00643,Mebendazole
below,27480864,bioavailability,"Oxantel pamoate could not be quantified, translating to a bioavailability below 0.025% in rats.","In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480864/),%,0.025,267182,DB00643,Mebendazole
